Carbinoxamine

Carbinoxamine
Systematic (IUPAC) name
2-[(4-chlorophenyl)-pyridin-2-yl-methoxy]-N,N-
dimethyl-ethanamine
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a606008
Pregnancy cat. C
Legal status 4 mg is FDA approved
Routes Oral: 4 mg tablet or 4 mg/5 mL liquid
Pharmacokinetic data
Half-life 10 to 20 hours
Identifiers
CAS number 486-16-8
ATC code R06AA08
PubChem CID 2564
DrugBank APRD00765
ChemSpider 2466 YesY
UNII VED9E376NC YesY
KEGG D07617 YesY
ChEBI CHEBI:3398 YesY
ChEMBL CHEMBL864 YesY
Chemical data
Formula C16H19ClN2O 
Mol. mass 290.788 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Carbinoxamine (Clistin, Palgic) antihistamine and anticholinergic. It was first launched in the United States by the McNeil Corporation under the brand name Clistin. It is now available under the brand name Palgic as 4 mg tablets or 4 mg/5 mL liquid. It is approved by the U.S. Food and Drug Administration (FDA) (specifically at the 4 mg dose/strength) for hay fever (a.k.a. allergic rhinitis, SAR and PAR); vasomotor rhinitis; mild urticaria; angioedema, dermatographism and allergic conjunctivitis.

In June 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed, and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older.[1]

References

External links